General Urology

What sounds good in theory falls short in practice

Hydrogel occlusion of vas achieves azoospermia quickly, maintained for a month

Complete responses in 73% of patients with BCG-unresponsive non-muscle-invasive disease

Two studies suggest no harm from deferred cytoreduction, potential benefits of immunotherapy

40% of women who received a 3-month course of MV140 had no UTIs during 9-month follow-up

Vasectomy consults more than doubled in the 3 months after Dobbs compared with the year before

ORR of 30% in patients with CD70-positive disease using off-the-shelf, allogeneic product

Enfortumab vedotin plus pembrolizumab approved for cisplatin-ineligible patients

Duration of response reaches 18.6 months with belzutifan plus cabozantinib

Also in TTHealthWatch: genes, a bacterium, and gastric cancer

Was also as effective as solifenacin in the majority of assessed efficacy endpoints

ZIRCON trial meets sensitivity and specificity targets

To increase participation, let's reduce the points of friction

Three different dosages of hydrochlorothiazide no better than placebo